Zhang et al. have provided some evidence that c-Myc, with the assistance of Sp1, modulates drug resistance in LSCs via promoting the expression of survivin.356 Therefore, c-Myc inhibition or depletion would be an intriguing tool for a regimen that targets both LSCs and the bulk AML cell population. This evidence concerns the gene MYC and acute myeloid leukemia.